for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurobindo Pharma Ltd

ARBN.NS

Latest Trade

514.95INR

Change

-84.80(-14.14%)

Volume

10,931,619

Today's Range

489.40

 - 

539.80

52 Week Range

389.35

 - 

838.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
599.75
Open
539.80
Volume
10,931,619
3M AVG Volume
88.54
Today's High
539.80
Today's Low
489.40
52 Week High
838.00
52 Week Low
389.35
Shares Out (MIL)
585.90
Market Cap (MIL)
351,416.70
Forward P/E
--
Dividend (Yield %)
0.50

Next Event

Full Year 2020 Aurobindo Pharma Ltd Earnings Release

Latest Developments

More

Aurobindo Pharma Ltd Dec Qtr Consol Profit Falls

India's Aurobindo Pharma's Unit VII Facility Classified By FDA As Official Action Indicated

Aurobindo Pharma Sept-Qtr Consol Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.

Contact Info

Water Mark Building,, Plot No. 11

Survey no.9, Kondapur, Hitech City

Hyderabad,Telangana

+91.40.66725000

http://www.aurobindo.com

Executive Leadership

K. Ragunathan

Non-Executive Independent Chairman of the Board

K. Nityananda Reddy

Whole-Time Vice Chairman of the Board, a promoter of the Company

Santhanam Subramanian

Chief Financial Officer

B. Adi Reddy

Compliance Officer, Company Secretary

N. Govindarajan

Managing Director, Executive Director

Key Stats

1.71 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

148.4K

2018

162.3K

2019

195.6K

2020(E)

231.4K
EPS (INR)

2017

39.330

2018

41.360

2019

41.860

2020(E)

46.979
Price To Earnings (TTM)
13.69
Price To Sales (TTM)
1.58
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
10.08
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Aurobindo Pharma Says U.S. FDA's VAI Issued On Feb 18 Rescinded

* GETS NOTICE THAT INSPECTION AT UNIT IV BY U.S. FDA STILL OPEN AND UNDER REVIEW

BRIEF-Aurobindo Pharma Gets VAI Status From U.S. FDA For Facility

* AUROBINDO PHARMA LTD -RECEIVED EIR WITH VOLUNTARY ACTION INITIATED STATUS FROM USFDA FOR UNIT 4, INJECTABLE FORMULATION MANUFACTURING FACILITY Source text for Eikon: Further company coverage:

BRIEF-Novartis says Zolgensma delay in Europe, Japan due to manufacturing questions from regulators

* SANDOZ Q3 OPERATING INCOME WAS USD 191 MILLION (-47%, -42% CC) IMPACTED BY CHANGES IN LEGAL SETTLEMENT PROVISIONS, HIGHER NET MANUFACTURING AND SANDOZ TRANSFORMATION RESTRUCTURING EXPENSES AND LOWER DIVESTMENT INCOME

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.

India's Aurobindo Pharma Q2 profit falls nearly 22 pct

Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

Novartis sells parts of Sandoz US to India's Aurobindo for $900 mln

Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

BRIEF-Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo

* NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO

BRIEF-Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz

* UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA

India's Aurobindo Pharma Q1 profit misses estimates

Aurobindo Pharma Ltd reported a 12 percent fall in quarterly profit on Thursday and missed analysts' expectations, hurt by higher expenses.

India's Aurobindo Pharma Q4 profit misses estimates

India's Aurobindo Pharma Ltd posted a 0.6 percent fall in fourth-quarter net profit on Monday that missed analysts' estimates.

BRIEF-Aurobindo Pharma Says U.S. FDA Issued Form 483 With 9 Observations for Co's Unit

* AUROBINDO PHARMA LTD CLARIFIES ON NEWS ITEM ON CO'S UNIT 4 GETTING 9 OBSERVATIONS AFTER U.S. FDA INSPECTION

BRIEF-Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share

* SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE Source text for Eikon: Further company coverage:

Aurobindo Pharma Q3 profit up about 3 pct, misses estimates

Aurobindo Pharma Ltd, India's third largest drugmaker by revenue, posted an about 3 percent rise in quarterly profit on Wednesday, but missed analysts' estimates.

BRIEF-India's Aurobindo Pharma Dec-Qtr Consol Net Profit Rises About 3 Pct

* DEC QUARTER CONSOL NET PROFIT 5.95 BILLION RUPEES VERSUS 5.79 BILLION RUPEES LAST YEAR

BRIEF-Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection

* SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION Source text - http://bit.ly/2pK1kNR Further company coverage:

BRIEF-Aurobindo Pharma Says News On Co Being Frontrunner to Buy Orchid Pharma "Factually Incorrect"

* AUROBINDO PHARMA CLARIFIES ON NEWS ITEM, "AUROBINDO, DR REDDY'S LABORATORIES FRONTRUNNERS TO BUY OUT BANKRUPT ORCHID PHARMA"

Aurobindo Pharma Q2 profit rises 29 pct, beats estimates

India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

BRIEF-Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC

* Says received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg

BRIEF-Aurobindo Pharma gets USFDA approval for drugs used for treatement of HIV-1 infection

* Receives USFDA tentative approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate tablets

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up